HUTCHMED: Neoplasms trials
The registry lists 13 Neoplasms studies with HUTCHMED as lead sponsor. 1 are open to participants now and 1 have results posted.
Phase 1 12Phase 2 4(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of HMPL-415S1 in Patients With Advanced Malignant Solid TumorsRecruitingNCT05886374Phase 1
- Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid TumorsTerminatedNCT04579757Phase 1/2Results posted
- A Phase I Clinical Study of HMPL-A83 in Patients With Advanced Malignant NeoplasmCompletedNCT05429008Phase 1
- A Study of HMPL-295S1 in Patients With Advanced Malignant Solid TumorsCompletedNCT04908046Phase 1
- A Study of HMPL-306 in Patients With IDH1 and/or IDH2 Mutation of Relapsed/Refractory Myeloid Leukemia/NeoplasmsStatus unknownNCT04272957Phase 1
- Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid TumorsCompletedNCT04169672Phase 2
- : A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid TumorsCompletedNCT03903705Phase 1/2
- A Study of HMPL-453 in Patients With Advanced Solid MalignanciesStatus unknownNCT03160833Phase 1/2
- A Dose Escalation Study to Assess the Safety and Tolerability of HMPL-453 in Patients With Advanced Solid MalignanciesTerminatedNCT02966171Phase 1
- A Study of Hutchison MediPharma Limited(HMPL)-523 in Patients With Relapsed or Refractory Mature B-cell NeoplasmsCompletedNCT02857998Phase 1
- A Phase I Study of Epitinib(HMPL-813) in Patients With Advanced Solid TumorsCompletedNCT02590952Phase 1
- A Study of HMPL-523 in Relapsed or Refractory Hematologic MalignanciesStatus unknownNCT02503033Phase 1
- Phase I Study of Sulfatinib(HMPL-012) in Patients With Advanced Solid TumorsCompletedNCT02133157Phase 1